Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

2.47USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
161,061
52-wk High
$2.55
52-wk Low
$0.74

Chart for

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.06
Market Cap(Mil.): $378.74
Shares Outstanding(Mil.): 153.34
Dividend: --
Yield (%): --

Financials

  DRRX.OQ Industry Sector
P/E (TTM): -- 199.23 33.71
EPS (TTM): -0.03 -- --
ROI: -15.07 -0.66 13.09
ROE: -24.78 -2.84 14.92

BRIEF-Durect Announces FDA Advisory Committee Meeting For Remoxy Er

* DURECT ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY® ER

Mar 20 2018

BRIEF-Durect Corporation Qtrly Earnings Per Share ‍$0.05​

* ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND UPDATE OF PROGRAMS

Mar 01 2018

BRIEF-Durect Corp Says Commenced Patient Dosing In A Phase 2A Clinical Trial Of Dur-928

* DURECT CORP SAYS COMMENCED PATIENT DOSING IN A PHASE 2A CLINICAL TRIAL OF DUR-928 IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) - SEC FILING

Feb 26 2018

BRIEF-Durect reports Q3 earnings per share of ‍$0.04​

* Durect Corporation announces third quarter 2017 financial results and provides corporate update

Nov 01 2017

BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

* Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint

Oct 19 2017

Earnings vs. Estimates